D11AX21 brimonidine

DERMATOLOGICALS OTHER DERMATOLOGICAL PREPARATIONS OTHER DERMATOLOGICAL PREPARATIONS Other dermatologicals

非健保收載 TFDA 在效許可證 3 FDA 已核准

台灣藥品與外觀

台灣食藥署在效西藥許可證 3 張;以下列出 3 個品項。

無外觀照
敏立紓凝膠
無外觀照
溴亞胺咪唑酒石酸鹽
無外觀照
溴莫尼丁酒石酸鹽

資料來源:食藥署「西藥許可證」+「藥品 ATC 碼」+「藥品外觀」+「藥品仿單或外盒」開放資料。外觀照與仿單連結指向食藥署原始檔。

適應症

台灣 TFDA 核准適應症

  1. 適用於成人病人、作為酒糟鼻臉部紅斑的症狀治療。
  2. 開放角隅青光眼或高眼壓。
  3. 青光眼治療藥。

美國 FDA 適應症(英文原文對照)

美國 FDA 核准成分 brimonidine tartrate and timolol maleate (商品名 Brimonidine Tartrate and Timolol Maleate / Brimonidine Tartrate/Timolol Maleate / LUMIFY Redness Reliever Eye Drops) · 仿單更新 2026-03-31

1 INDICATIONS AND USAGE Brimonidine tartrate and timolol maleate ophthalmic solution 0.2% /0.5% is an alpha-adrenergic receptor agonist with a beta-adrenergic receptor inhibitor indicated for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP; the IOP-lowering of Brimonidine tartrate and timolol maleate ophthalmic solution dosed twice a day was slightly less than that seen with the concomitant administration of 0.5% timolol maleate ophthalmic solution dosed twice a day and 0.2% brimonidine tartrate ophthalmic solution dosed three times per day. Brimonidine tartrate and timolol maleate ophthalmic solution is an alpha-adrenergic receptor agonist with a beta-adrenergic receptor inhibitor indicated for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP; the IOP-lowering of Brimonidine tartrate and timolol maleate ophthalmic solution dosed twice a day was slightly less than that seen with the concomitant administration of timolol maleate ophthalmic solution, 0.5% dosed twice a day and brimonidine tartrate ophthalmic solution, 0.2% dosed three times per day.

資料來源:食藥署西藥許可證適應症(中文)、openFDA US SPL(英文,僅供對照)。

健保給付規定

查無健保特殊給付規定條款;本藥品依一般健保藥品支付規定給付。

實證補充

本藥品尚無實證補充整理(未來新增 Review/指引知識時補列)。


台灣藥品與適應症:食藥署西藥許可證+ATC+外觀+仿單開放資料 · FDA:openFDA US SPL · 健保給付:健保署「全民健康保險藥品給付規定」(更新日 2026-06-09)· 實證補充:人工彙整。 本頁為資訊整理,實際給付與適應症以主管機關公告為準。